Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.41 |
| ▸ | AOC2 | O75106 | 5/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808826 | 1.00 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2449240 | 0.78 | MAOA (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16429466 | 0.78 | CA2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1567977 | 0.78 | CA2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5722720 | 0.74 | MAOB (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29935960 | 0.74 | MAOB (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2395914 | 0.74 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL36938 | 0.74 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17891950 | 0.74 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL765957 | 0.73 | BRD4 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488510-B1 | Amides and thioamides as pest control agents | BAYER IP GMBH (DE) | 2017-03-29 | — | — | EP | claimed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | claimed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | claimed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | claimed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | claimed |
| US-20130072471-A1 | Inhibitors of Ion Channels | MARRON BRIAN EDWARD (US) | 2013-03-21 | — | — | US | claimed |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-10-04 | — | — | US | claimed |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-02-09 | — | — | US | claimed |
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | claimed |
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | US | claimed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | claimed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | claimed |
| US-6617281-B1 | Substituted acylamino phenyl uracils | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | claimed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| EP-1095028-A1 | SUBSTITUTED ACYLAMINO PHENYL URACILS | BAYER AG (DE) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002867-A1 | SUBSTITUTED ACYLAMINO PHENYL URACILS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | claimed |
| WO-1998002435-A1 | NOVEL BENZODIOXANES AND 1-(2H)-BENZOPYRANES, THEIR PREPARATION AND THEIR USE AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-01-22 | — | — | WO | claimed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | CHRM2 599/4885CHRM4 564/4885CHRM5 978/4885 |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | CHRM2 599/4885CHRM4 564/4885CHRM5 978/4885 |
| US-20130072471-A1 | Inhibitors of Ion Channels | TRPV1, TRPV5, TRPA1 | CHRM2 3000/4885CHRM4 2637/4885CHRM5 1791/4885 |
| US-20120035158-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | CHRM2 599/4885CHRM4 564/4885CHRM5 978/4885 |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | CHRM2 599/4885CHRM4 564/4885CHRM5 978/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | CHRM2 2991/4885CHRM4 2438/4885CHRM5 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.